Johnson & Johnson Expands U.S. Availability Of Intraocular Lens

Johnson & Johnson has broadened U.S. access to a new intraocular lens designed for patients having cataract surgery who want better vision across a range of distances. The move is notable because the lens is an extended depth of focus (EDOF) option, a category that aims to reduce dependence on reading glasses while avoiding some common visual side effects of earlier multifocal designs.

Future Impact on Patient Care

Johnson & Johnson’s FDA approval and subsequent commercial rollout of the TECNIS PureSee Extended Depth of Focus (EDOF) Intraocular Lens (IOL) represent a highly anticipated leap forward in the field of ophthalmic surgery. Based on the data, clinical trials, and insights shared across the provided articles, this milestone reshapes what patients and eye surgeons can expect from modern cataract care.

Why It Matters

Cataract surgery is one of the most common procedures performed in older adults. Previously, cataract surgery forced a frustrating compromise. Standard monofocal lenses provided excellent, sharp distance vision but left patients entirely dependent on reading glasses for anything up close, like reading a text message or looking at a car dashboard. For decades, the standard goal was to remove the cloudy lens and restore clear distance vision using a simple monofocal intraocular lens. That still works well. But many patients now expect more. They want sharper vision for intermediate tasks like computer work and better near vision for phones and reading, ideally without relying on glasses. That expectation has driven demand for advanced IOLs and, for surgeons, introduced a series of trade-offs.

New Technology

On the flip side, multifocal and early extended depth of focus (EDOF) lenses broadened that visual range but introduced trade-offs. The physics behind those older premium lenses often resulted in a noticeable loss of contrast sensitivity (making it hard to see in low-light, foggy, or dim environments) and caused annoying visual side effects like halos and glare at night.

The TECNIS PureSee matters immensely because it bridges this historical gap. It is the first and only FDA-approved EDOF lens in the United States without a warning regarding a loss of contrast sensitivity. By demonstrating that its contrast performance is clinically comparable to a standard aspheric monofocal lens, J&J has eliminated a major clinical hurdle. Furthermore, during its pivotal U.S. clinical trial, an astonishing 97% of patients reported experiencing no highly bothersome visual disturbances, and 97% stated they would recommend the lens to friends or family. It essentially delivers the expanded visual range patients want without sacrificing the low-light clarity they need.

Extended depth of focus lenses aim to extend the range of useful vision by altering the lens optics so the eye can focus over a broader range. Compared with older multifocal lenses, EDOF technology emphasizes continuous, more natural transitions between near and far and can produce fewer visual disturbances such as glaring halos or problematic night-time glare. Those differences matter because even a small amount of bothersome visual disturbance can lead patients to regret their choice of a premium lens and prompt additional office visits and corrective procedures.

Impacts on Patient Access

When a large manufacturer makes an EDOF lens broadly available, it changes the conversation in several ways. Clinicians get another option to match to individual patients. Health systems and surgical centers may weigh stocking and training costs against the demand for higher-value, patient-satisfying outcomes. And payers must decide how to handle the added expense of premium lenses, which patients often pay out of pocket. The bottom line is that broader availability is not just about a device on the shelf. It is about expectations, counseling, and the economics of care delivery.

Who It Affects

Patients

Patients with cataracts are the most obvious group. Many will still choose a standard monofocal lens, particularly if they are comfortable with reading glasses. But a growing subset—people who remain in the workforce, active retirees, or those who prioritize reduced dependence on spectacle—is a prime candidate for EDOF lenses. For these patients, the promise is improved intermediate vision and fewer trade-offs in night driving and contrast sensitivity. That said, expectations must be managed. No current lens perfectly restores the full range of youthful vision, and outcomes vary with each patient’s eye health and anatomy.

Another subset of patients includes those with cataracts and presbyopia. This primarily affects adults over 50 facing the dual challenge of cataracts (the natural clouding of the eye’s lens) and presbyopia (the gradual loss of near-focus ability). Globally, an estimated 94 million people live with moderate-to-severe distance vision impairment that could be corrected via lens replacement surgery. For these individuals, this lens offers a chance to restore clear vision and dramatically reduce dependency on glasses.

Patients with Corneal Astigmatism are an additional patient population that is affected by this FDA approval. The approval is highly inclusive. While the standard TECNIS PureSee (Model ZEN00V) is indicated for patients with less than 1.0 diopter (D) of pre-existing corneal astigmatism, J&J also secured approval for the TECNIS PureSee Toric II, making this advanced technology accessible to patients with 1.0 D or greater of preoperative astigmatism.

Clinicians – Surgeons and Surgical Teams

Surgeons and surgical teams are also affected. Adding a new intraocular lens to the menu requires surgeons to learn the subtle selection criteria and surgical nuances that influence outcomes. Proper patient selection is critical. Patients with other eye conditions, such as advanced macular disease or significant corneal irregularity, including high astigmatism, may not get the expected benefits. The availability of a non-toric EDOF lens means surgeons must decide whether to combine it with other corrective techniques or to choose an alternative lens that directly addresses astigmatism.

For eye care providers, ophthalmologists, and optometrists, this rollout expands their clinical toolkit. It gives surgeons a reliable, premium, non-diffractive lens option for patients who lead active lifestyles—such as frequent night drivers, golfers, or digital device users—and demand high-quality visual performance across varying lighting conditions.

Health Systems and Surgical Centers

Health systems and ambulatory surgical centers face both clinical and operational decisions. Stocking a premium lens involves inventory management, staff training, and patient education resources. It also raises billing questions. Many payers view advanced IOLs as an elective upgrade and leave the additional cost to patients. That reality shapes who ends up accessing these technologies and how clinics counsel patients about expected out-of-pocket costs.

Payers and Policymakers

Payers and policymakers should take note as well. As the population ages and demand for vision-enhancing options grows, payers will be pressed to decide how much value they place on improved functional vision and reduced downstream costs from spectacle use. Those policy choices will influence uptake and equity in access across different socioeconomic groups.

What Changes

• Surgeons will have a new EDOF intraocular lens option to offer patients who want a broader range of vision while minimizing common visual disturbances.
• Patient counseling needs to be sharper. Clinicians should set realistic expectations about likely improvements, residual need for reading glasses, and possible side effects such as glare, halos, or reduced contrast sensitivity.
• Clinics and surgical centers should prepare operationally by ensuring that stock management, informed consent materials, and staff education on lens selection and post-operative follow-up are in place.
• Access and cost will remain central issues. Payers may not cover the premium portion of advanced lenses, so patients should understand the financial implications before choosing an upgrade.

Up Next: Real-World Performance

There are a few additional, practical points worth flagging. First, real-world performance matters more than marketing claims. Device makers often report high patient satisfaction rates, but surgeons know that published claims do not replace careful preoperative assessment. Second, the presence of other eye diseases changes the equation. A lens that works beautifully in an otherwise healthy eye can perform poorly when macular or corneal problems are present. Third, long-term follow-up studies and broader post-market data will help clarify whether earlier reported benefits hold up across diverse patient populations and settings.

Patient Perspectives

From a patient perspective, choosing an advanced IOL is increasingly a lifestyle and values decision. Some people are willing to pay for a chance at less dependence on glasses. Others prioritize minimizing any risk of visual disturbances and will opt for a monofocal lens that reliably restores clear distance vision. Good counseling explains both paths clearly and documents that the choice was informed.

For practices, the commercial rollout of another EDOF lens means balancing marketing opportunity against clinical prudence. Clinics often see an increase in inquiries when a big company announces broader availability. That can be an opportunity to improve the quality of preoperative education and standardize how outcomes are measured and reported in the clinic. It can also highlight disparities. Practices that cater to wealthier patients may quickly adopt premium options, while safety-net providers may not, widening the gap in access to vision-enhancing technologies.

Looking Ahead

Looking forward, the landscape of cataract and refractive lens surgery will continue to evolve. Optical technologies will improve incrementally. Surgical techniques and preoperative imaging will get better at predicting which patients will benefit most. And payers may start to recognize the downstream benefits of reduced spectacle dependence for work productivity and quality of life. But those shifts will take time and evidence. For now, the key responsibilities fall on surgeons and clinics: make careful patient matches, clearly explain trade-offs and costs, and collect outcomes data to inform future practice.

In short, the expanded U.S. availability of a new intraocular lens is more than a corporate milestone. It is a reminder that cataract surgery is no longer just about removing clouded lenses. It is about choices, expectations, and the practicalities of delivering higher-functioning vision to people whose lives depend on it. Clinicians who take the time to explain benefits and limits will give patients the clearest path to a good outcome.

References

1. https://www.optometrytimes.com/view/fda-approves-johnson-johnson-s-tecnis-puresee-edof-iol
2. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients
3. https://www.ophthalmologytimes.com/view/tecnis-puresee-iol-launches-in-us-following-fda-approval-for-cataract-surgery